Essentials of Complementary and Alternative Medicine (June 1999)

C
HAPTER
 R
EFERENCES
1.
Campbell TC, Junshi C. Diet and chronic degenerative diseases: perspectives from China. Am J Clin Nutr 1994;59(5 Suppl):1153S–1161S.
2.
Department of Health and Human Services. Healthy People 2000. 1990. The baseline data source of this recommendation is the Continuing Survey of Food Intakes by Individuals, CSFII, 
USDA.
3.
Department of Health and Human Services. The Surgeon General's report, 1988.

4.
National Research Council. Diet and health: implications for reducing chronic disease risk. Washington, D.C.: National Academy Press, 1989.
5.
U.S. Dept. of Agriculture and U.S. Dept. of Health and Human Services. Dietary guidelines for Americans. Washington, D.C.: The Departments, 1990.
6.
Williams RJ. Biochemical individuality: the basis for the genetotrophic concept. Austin & London: University of Texas Press, 1977.
7.
Williams RJ, Beerstecher E, Berry LJ. The concept of genetotrophic disease. Lancet 1950;287–289.
8.
Davies S. Scientific and ethical foundations of nutritional and environmental medicine. Part II. Further glimpses of “the higher medicine.” J Nutr Environ Med 1995;5:5–11.
9.
Reynolds RD. Vitamin supplements: current controversies. J Am Coll Nutr 1994;13(2):118–126.
10.
Stewart AS. Medical applications of nutrition. In: 1986: a year in nutritional medicine. 2nd ed. New Canaan, CT: Keats Publishing, 1986:333–358.
11.
Bland JS. The nutritional effects of free radical pathology. In: 1986: a year in nutritional medicine. 2nd ed. New Canaan, CT: Keats Publishing, 1986:293–322.
12.
Werbach MR. Illnesses and the effects of nutrients, toxics and environmental sensitivities. In: Nutritional influences on illness. New Canaan, CT: Keats Publishing, 1988:3–448.
13.
Roe DA. Effects of drugs on vitamin needs. Ann N Y Acad Sci 1992;669:156–163.
14.
Roe DA. Drug-food and drug-nutrient interactions. J Environ Pathol Toxicol Oncol 1985;5(6):115–135.
15.
Roe DA. Drug effects on nutrient absorption, transport, and metabolism. Drug–Nutrient Interactions 1985;4(1–2):117–135.
16.
Filiberti R, Giacosa A, Brignoli O. High-risk subjects for vitamin deficiency. Eur J Cancer Prev 1997;6(suppl 1):S37–S42.
17.
Tonkin SY. Oral contraceptives and vitamin status. In: Briggs MH, ed. Vitamins in human biology and medicine. Boca Raton, FL: CRC Press, 1980:29–64.
18.
Stewart AS. Medical applications of nutrition. In: 1986: a year in nutritional medicine. 2nd ed. New Canaan, CT: Keats Publishing, 1986:333–358.
19.
Nikolaev MP, Logunov AI, Tsyrulnikova LG, Dzhalilov DS. Clinical and biochemical aspects in the treatment of acute maxillary sinusitis with antioxidants. Vestn Otorinolaringol 1994;1:22–26.
20.
Sorenson JR. Antiinflammatory, analgesic, and antiulcer activities of copper complexes suggest their use in a physiologic approach to treatment of arthritic diseases. Basic Life Sci 
1988;49:591–594.
21.
Sorenson JR. Copper complexes offer a physiological approach to treatment of chronic diseases. Prog Med Chem 1989;26:437–568.
22.
Cathcart ES, Gonnerman WA, Leslie CA, Hayes KC. Dietary n-3 fatty acids and arthritis. J Intern Med Suppl 1989;225(731):217–223.
23.
Leslie CA, Conte JM, Hayes KC, Cathcart ES. A fish oil diet reduces the severity of collagen induced arthritis after onset of the disease. Clin Exp Immunol 1988;73(2):328–332.
24.
Sorenson JR, Soderberg LS, Chidambaram MV, et al. Bioavailable copper complexes offer a physiologic approach to treatment of chronic diseases. Adv Exp Med Biol 1989;258:229–234.
25.
Arstall MA, Yang J, Stafford I, et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical 
effects. Circulation 1995;92(10):2855–2862.
26.
Wells RS, Higgs JM, Macdonald A, et al. Familial chronic muco-cutaneous candidiasis. J Med Genet 1972;9(3):302–310.
27.
Laurence DR, Bennett PN. Drugs used in tuberculosis. In: Clinical pharmacology. London: Churchill Livingstone, 1980:272–277.
28.
Chandra RK, Puri S. Nutritional support improves antibody response to influenza virus vaccine in the elderly. BMJ 1985;291:705–706.
29.
Walubo A. Smith PJ. Folb PI. Oxidative stress during antituberculous therapy in young and elderly patients. Biomed Environ Sci 1995;8(2):106–113.
30.
Hildenbrand G, Cavin S. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Therap Health Med 1995;1(4):29–37.
31.
Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998;280:2001–2007.
32.
McDougall J, Litzau K, Haver E, et al. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr 1995;14:491–496.
33.
Levine R. Monosaccharides in health and disease. Ann Review Nutr 1986;6:211–224.
34.
Rupp H. Insulin resistance, hyperinsulinemia, and cardiovascular disease. The need for novel dietary prevention strategies. Basic Res Cardiol 1992;87(2):99–105.
35.
Grimditch GK. Barnard RJ. Hendricks L. Weitzman D. Peripheral insulin sensitivity as modified by diet and exercise training. Am J Clin Nutr 1988;48(1):38–43.
36.
Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lip Res 1988;29(11):1451–1460.
37.
Connor WE. Effects of omega-3 fatty acids in hypertriglyceridemic states. Semin Thromb Hemost 1988;14(3):271–284.
38.
Clemens MR, Muller F, Ladner CI, Gey KF. Vitamine bei hochdosierter Chemo- und Strahlentherapie. Z Ernahrungswiss 1992;31:110–120.
39.
Clemens MR. Vitamins and therapy of malignancies. Therapeutische Umschau 1994;51(7):483–488.
40.
Jaakkola K, Lahteenmaki P, Laakso J, et al. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer 
Res 1992;12(3):599–606.
41.
Anonymous. Free radicals and breast cancer. Environ Health Perspect 1996;104(8):821.
42.
Fujita K, Shinpo K, Yamada K, et al. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 1982;42(1):309–316.
43.
Kobrinsky NL, Hartfield D, Horner H, et al. Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest 1996;14(3):202–210.
44.
Okunieff P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. Am J Clin Nutr 1991;54(6 Suppl):1281S–1283S.
45.
Pritsos CA, Sokoloff M, Gustafson DL. PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem Pharmacol 
1992;44(4):839–841.
46.
Schmitt-Graff A, Scheulen ME. Prevention of adriamycin cardiotoxicity by niacin, isocitrate or N-acetyl-cysteine in mice. A morphological study. Pathol Res Pract 1986;181(2):168–174.
47.
Pinto J, Raiczyk GB, Huang YP, Rivlin R. New approaches to the possible prevention of side effects of chemotherapy by nutrition. Cancer 1986;48:1911–1914.
48.
Myers CE, McGuire W, Young R. Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat Rep 1976;60(7):961–962.
49.
Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991;54(6 Suppl):1298S–1301S.
50.
Sugiyama S, Yamada K, Hayakawa M, Ozawa T. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome-encapsulated 
doxorubicin or combination therapy with antioxidant. Biochem Mol Biol Int 1995;36(5):1001–1007.
51.
Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull 
1993;16(11):1114–1117.
52.
Shinozawa S, Kawasaki H, Gomita Y. Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity 
and microsomal lipid peroxidation in mice. Japn J Cancer Res 1996;23(1):93–98.
53.
Tursz T. Combination of BRMs with chemotherapy. Am J Med 1995;99(suppl 6A):56S–58S.
54.
Israel L, Hajji O, Grefft-Alami A, et al. Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause. Randomized trial in 100 patients. Ann Med Intern 
1985;136(7):551–554.
55.
Komiyama S, Kudoh S, Yanagita T, Kuwano M. Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors–antitumor combination therapy 
with vitamin A. Auris Nasus Larynx 1985;12(suppl 2):S239–S243.
56.
Komiyama S, Hiroto I, Ryu S, et al. Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors. Oncology 1978;35(6):253–257.
57.
Teicher BA, Schwartz JL, Holden SA, et al. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother Pharmacol 1994;34(3):235–241.
58.
Meadows GG, Pierson HF, Abdallah RM. Ascorbate in the treatment of experimental transplanted melanoma. Am J Clin Nutr 1991;54(6 Suppl):1284S–1291S.
59.
Kurbacher CM, Wagner U, Kolster B, et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. 
Cancer Lett 1996;103(2):183–189.
60.
Taper HS, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 1987;40(4):575–579.
61.
Noto V, Taper HS, Jiang YH, et al. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of 
combined vitamin C and K3 action. Cancer 1989;63(5):901–906.
62.
Gilloteaux J, Jamison JM, Venugopal M, et al. Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C–vitamin K3 
combinations against human prostatic carcinoma cells. Scanning Microsc 1995;9(1):159–173.
63.
De Loecker W, Janssens J, Bonte J, Taper HS. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. II. 
Synergism with combined chemotherapy action. Anticancer Res 1993;13(1):103–106.
64.
Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. Anticancer Res 
1992;2(5):1651–1654.
65.
Boccardo F, Canobbio L, Resasco M, et al. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J Cancer Res Clin Oncol 1990;116(5):503–506.
66.
Recchia F, Sica G, de Filippis S, et al. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study. J Interferon Cytokine Res 1995;15(7):605–610.
67.
Israel L, Hajji O, Grefft-Alami A, et al. Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause. Randomized trial in 100 patients. Ann Intern Med 
1985;136(7):551–554.
68.
Recchia F, Rea S, Corrao G, et al. Sequential chemotherapy, beta interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. A pilot study. Eur J Cancer 
1995;31A(11):1887–1888.
69.
Recchia F, Rea S, Pompili P, et al. Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Clinica Terapeutica 1995;146(10):603–610.
70.
Recchia F, Frati L, Rea S, et al. Minimal residual disease in metastatic breast cancer: treatment with IFN-beta, retinoids, and tamoxifen. J Interferon Cytokine Res 1998;18(1):41–47.
71.
Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk' patients supplemented with nutritional antioxidants, essential fatty acids and 
coenzyme Q10. Mol Aspects Med 1994;15(Suppl):231–240.
72.
Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophysi Res Comm 
1994;199(3):1504–1508.
73.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Comm 
1995;212(1):172–177.
74.
Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Comm 1993;192(1):241–245.
75.
Brittenden J, Heys SD, Miller I, et al. Dietary supplementation with L-arginine in patients with breast cancer (4 cm) receiving multimodality treatment: report of a feasibility study. Br J Cancer 
1994;69(5):918–921.
76.
Heys SD, Sarkar TK, Ah-See AK, et al. Multimo-dality treatment in the management of locally advanced breast cancer. J R Coll Surg Edinb 1993;38(1):9–15.
77.
Nole F, de Braud F, Aapro M, et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low 
subjective toxic burden. Ann Oncol 1997;8(9):865–870.
78.
Parnes HL, Abrams JS, Tait N, et al. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma. J Natl Cancer Inst 
1991;83(14):1017–1020.
79.
Hainsworth JD, Jolivet J, Birch R, et al. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line 

chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. Cancer 1997;79(4):740–748.
80.
Ribas A, Albanell J, Sole-Calvo LA, et al. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. 
Cancer 1998;82(5):878–885.
81.
Klaassen U, Wilke H, Weyhofen R, et al. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of 
metastatic breast cancer. Anticancer Drugs 1998;9(3):203–207.
82.
Gregorio DI, Emrich LJ, Graham S, et al. Dietary fat consumption and survival among women with breast cancer. J Natl Cancer Inst 1985;75(1):37–41.
83.
Nomura AM, Marchand LL, Kolonel LN, et al. The effect of dietary fat on breast cancer survival among Caucasian and Japanese women in Hawaii. Breast Cancer Res Treat 1991;18(Suppl 
1):S135–S141.
84.
Sopotsinskaia EB, Balitskii KP, Tarutinov VI, et al. Experience with the use of a low-calorie diet in breast cancer patients to prevent metastasis. Vopr Onkol 1992;38(5):592–599.
85.
Holm LE, Nordevang E, Hjalmar ML, et al. Treatment failure and dietary habits in women with breast cancer. J Natl Cancer Inst 1993;85(1):32–36.
86.
Rohan TE, Hiller JE, McMichael AJ. Dietary factors and survival from breast cancer. Nutr Cancer 1993;20(2):167–177.
87.
Jain M, Miller AB, To T. Premorbid diet and the prognosis of women with breast cancer. J Natl Cancer Inst 1994;86(18):1390–1397.
88.
Zhang S, Folsom AR, Sellers TA, et al. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 
1995;76(2):275–283.
89.
Jain M, Miller AB. Tumor characteristics and survival of breast cancer patients in relation to premorbid diet and body size. Breast Cancer Res Treat 1997;42(1):43–55.
90.
Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11(7):1216–1222.
91.
Thiruvengadam R, Atiba JO, Azawi SH. A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Invest New Drugs 
1996;14(4):395–401.
92.
Meyskens FL Jr, Gilmartin E, Alberts DS, et al. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 1982;66(6):1315–1319.
93.
Friedland D, Luginbuhl W, Meehan L, et al. Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. Proc ASCO 1994;6:712.
94.
Arnold A, Ayoub J, Douglas L, et al. Phase II trial of 13-cis-retinoic acid plus interferon-alpha in non-small-cell lung cancer. J Natl Cancer Inst 1994;86(4):306–309.
95.
Roth AD, Abele R, Alberto P. 13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck. Oncology 1994;51(1):84–86.
96.
Uphouse W, Oishi N, Berenberg J, et al. Treatment of advanced non-small cell lung cancer with 13-cis-retinoic acid. Proc ASCO 1987;6:712.
97.
Grunberg SM, Itri LM. Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 1987;71(11):1097–1098.
98.
Jaakkola K, Lahteenmaki P, Laakso J, et al. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer 
Res 1992;12(3):599–606.
99.
Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977;10(6):556–561.
100.
Alfthan O, Tarkkanen J, Grohn P, et al. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur Urol 1983;9(1):6–9.
101.
Studer UE, Biedermann C, Chollet D, et al. Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland. 
J Urol 1984;131(1):47–49.
102.
Yoshida O, Miyakawa M, Watanabe H, et al. Prophylactic effect of etretinate on the recurrence of superficial bladder tumors–results of a randomized control study. Hinyokika Kiyo 
1986;32(9):1349–1358.
103.
Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, 
randomized multicenter trial in Switzerland. Eur Urol 1995;28(4):284–290.
104.
Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994;151(1):21–26.
105.
Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. 
Blood 1993;82(11):3241–3249.
106.
Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337(15):1021–1028.
107.
Latagliata R, Avvisati G, Lo Coco F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol 
1997;8(12):1273–1275.
108.
Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337(15):1021–1028.
109.
Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 
1995;85(5):1202–1206.
110.
Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120(4):278–286.
111.
Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. 
Blood 1993;82(11):3241–3249.
112.
Thomas X, Anglaret B, Thiebaut A, et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann 
Hematol 1997;75(5–6):195–200.
113.
Ohno R, Ohnishi K, Takeshita A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 
1994;8(Suppl3):S64–S69.
114.
Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute pro-myelocytic leukemia. Cancer 1994;73(12):2946–2952.
115.
Ohno R, Yoshida H, Fukutani H, et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia Study Group of the 
Ministry of Health and Welfare. Leukemia 1993;7(11):1722–1727.
116.
Liang R, Chow WS, Chiu E, et al. Effective salvage therapy using all-trans retinoic acid for relapsed and resistant acute promyelocytic leukemia. Anticancer Drugs 1993;4(3):339–340.
117.
Hildenbrand GL, Hildenbrand LC, Bradford K, Cavin SW. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern 
Therap Health Med 1995;1(4):29–37.
118.
Demopoulos HB. Effects of reducing the phenylalanine-tyrosine intake of patients with advanced malignant melanoma. Cancer 1966;19(5): 657–664.
119.
Rustin GJ, Dische S, de Garis ST, Nelstrop A. Treatment of advanced malignant melanoma with interferon alpha and etretinate. Eur J Cancer Clin Oncol 1988;24(4):783–784.
120.
Triozzi PL, Walker MJ, Pellegrini AE, Dayton MA. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 1996;14(4):293–298.
121.
Fierlbeck G, Schreiner T, Rassner G. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol 
Immunother 1995;40(3):157–164.
122.
The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC V). Arch Intern Med 1993;153:154–183.
123.
Working Group on Primary Prevention of Hypertension. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 
1993;153:186–208.
124.
Gillum RF, Prineas RJ, Jeffery RW, et al. Nonpharmacologic therapy of hypertension: the independent effects of weight reduction and sodium restriction in overweight borderline hypertensive 
patients. Am Heart J 1983;105(1):128–133.
125.
Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial–the Hypertension Control Program. JAMA 
1987;257(11):1484–1491.
126.
Prineas RJ. Clinical interaction of salt and weight change on blood pressure level. Hypertension 1991;17(1 Suppl):I143–I149.
127.
Beilin LJ. Non-pharmacological management of hypertension: optimal strategies for reducing cardiovascular risk. J Hypertens Suppl 1994;12(10): S71–S81.
128.
Efstratopoulos AD, Voyaki SM. Effect of anti-oxidants on acute blood pressure response to smoking in normotensives and hypertensives. J Hypertens Suppl 1993;11(Suppl 5):S112–S113.
129.
Tse WY, Maxwell SR, Thomason H, et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens 1994;8(11):843–849.
130.
Lavie CJ, Milani RV, Ventura HO, et al. Cardiac rehabilitation, exercise training, and preventive cardiology research at Ochsner Heart and Vascular Institute. Tex Heart Inst J 1995;22(1):44–52.
131.
Barnard RJ, Wen SJ. Exercise and diet in the prevention and control of the metabolic syndrome. Sports Med 1994;18(4):218–228.
132.
McKnight JA, Moore TJ. The effects of dietary factors on blood pressure. Compr Ther 1994;20(9):511–517.
133.
Oberman A, Wassertheil-Smoller S, Langford HG, et al. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med 1990;112(2):89–95.
134.
Moore TJ, McKnight JA. Dietary factors and blood pressure regulation. Endocrinol Metab Clin North Am 1995;24(3):643–655.
135.
Beilin LJ. Non-pharmacological management of hypertension: optimal strategies for reducing cardiovascular risk. J Hypertens Suppl 1994;12(10): S71–S81.
136.
Stein PP, Black HR. The role of diet in the genesis and treatment of hypertension. Med Clin North Am 1993;77(4):831–847.
137.
McCarron DA, Henry HJ, Morris CD. Human nutrition and blood pressure regulation: an integrated approach. Hypertension 1982;4(5 Pt 2):III2–III13.
138.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336(16):1117–1124.
139.
Beilin LJ. Vegetarian and other complex diets, fats, fiber, and hypertension. Am J Clin Nutr 1994;59(5 Suppl):1130S–1135S.
140.
Rouse IL, Armstrong BK, Beilin LJ. Vegetarian diet, lifestyle and blood pressure in two religious populations. Clin Exp Pharmacol Physiol 1982;9(3):327–330.
141.
Melby CL, Goldflies DG, Hyner GC, Lyle RM. Relation between vegetarian/nonvegetarian diets and blood pressure in black and white adults. Am J Public Health 1989;79(9):1283–1288.
142.
McCarron DA, Oparil S, Resnick LM, et al. Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension. Am J Hypertens 1998;11(1 Pt 1):31–40.
143.
McDougall J, Litzau K, Haver E, et al. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr 1995;14(5):491–496.
144.
Sacks FM, Donner A, Castelli WP, et al. Effect of ingestion of meat on plasma cholesterol of vegetarians. JAMA 1981;246(6):640–644.
145.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336(16):1117–1124.
146.
Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomized controlled trial. Br Med J (Clin Res Ed) 1986;293(6560):1468–1471.
147.
Rouse IL, Beilin LJ, Mahoney DP, et al. Nutrient intake, blood pressure, serum and urinary prostaglandins and serum thromboxane B2 in a controlled trial with a lacto-ovo-vegetarian diet. J 
Hypertens 1986;4(2):241–50
148.
Anonymous. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. 
BMJ 1988;297(6644):319–328.
149.
Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions 
in the elderly (TONE). TONE Collaborative Research Group JAMA 1998;279(11): 839–846.
150.
Gillum RF, Prineas RJ, Jeffery RW, et al. Nonpharmacologic therapy of hypertension: the independent effects of weight reduction and sodium restriction in overweight borderline hypertensive 
patients. Am Heart J 1983;105(1):128–133.
151.
Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial–the Hypertension Control Program. JAMA 

1987;257(11):1484–1491.
152.
Prineas RJ. Clinical interaction of salt and weight change on blood pressure level. Hypertension 1991;17(1 Suppl):I143-I149.
153.
Cappuccio FP, Markandu ND, Carney C, et al. Double-blind randomized trial of modest salt restriction in older people. Lancet 1997;350(9081):850–4
154.
Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997;277(20):1624–1632.
155.
Fotherby MD, Potter JF. Long-term potassium supplementation lowers blood pressure in elderly hypertensive subjects. Int J Clin Pract 1997;51(4):219–222.
156.
Langford HG. Dietary potassium and hypertension: epidemiologic data. Ann Intern Med 1983;98(5 Pt 2):770–772.
157.
Sorof JM, Forman A, Cole N, et al. Potassium intake and cardiovascular reactivity in children with risk factors for essential hypertension. J Pediatr 1997;131(1 Pt 1):87–94.
158.
Hoes AW, Grobbee DE, Lubsen J. Sudden cardiac death in patients with hypertension. An association with diuretics and beta-blockers? Drug Saf 1997;16(4):233–241.
159.
Geleijnse JM, Witteman JC, den Breeijen JH, et al. Dietary electrolyte intake and blood pressure in older subjects: the Rotterdam Study. J Hypertens 1996;14(6):737–741.
160.
Witteman J, Stampfer MJ. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 1996;27(5):1065–1072.
161.
Ozono R, Oshima T, Matsuura H. Systemic magnesium deficiency disclosed by magnesium loading test in patients with essential hypertension. Hypertens Res 1995;18(1):39–42.
162.
McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt-sensitive hypertension. Am J Clin Nutr 1997;65(2 Suppl):712S–716S.
163.
Witteman JC, Willett WC, Stampfer MJ, et al. A prospective study of nutritional factors and hypertension among U.S. women. Circulation 1989;80(5):1320–1327.
164.
McCarron D, Morris C. Blood pressure response to oral calcium in persons with mild to moderate hypertension. Ann Intern Med 1985;103:825–829.
165.
Giovannucci E, Rimm EB, Wolk A, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998;58(3):442–447.
166.
Seelig MS. Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, migraine and premenstrual syndrome. J Am Coll Nutr 1993;12(4):442–458.
167.
Bonaa KH, Bjerve KS, Straume B, et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromso study. 
N Engl J Med 1990;322(12): 795–801.
168.
Cobiac L, Nestel PJ, Wing LM, Howe PR. A low-sodium diet supplemented with fish oil lowers blood pressure in the elderly. J Hypertens 1992;10(1):87–92.
169.
Iacono JM, Dougherty RM, Puska P. Dietary fats and the management of hypertension. Can J Physiol Pharmacol 1986;64(6):856–862.
170.
Puska P, Iacono JM, Nissinen A, et al. Controlled, randomized trial of the effect of dietary fat on blood pressure. Lancet 1983;1:1–5.
171.
Puska P, Nissinen A, Pietinen P, Iacono J. Role of dietary fat in blood pressure control. Scand J Clin Lab Invest Suppl 1985;176:62–69.
172.
Kendler BS. Garlic (Allium sativum) and onion (Allium cepa): a review of their relationship to cardiovascular disease. Prev Med 1987;16(5):670–685.
173.
Orekhov AN, Grunwald J. Effects of garlic on atherosclerosis. Nutrition 1997;13(7–8):656–663.
174.
Auer W, Eiber A, Hertkorn E, et al. Hypertension and hyperlipidaemia: garlic helps in mild cases. Br J Clin Pract Suppl 1990;69:3–6.
175.
Vorberg G, Schneider B. Therapy with garlic: results of a placebo-controlled, double-blind study. Br J Clin Pract Suppl 1990;69:7–11.
176.
McMahon FG, Vargas R. Can garlic lower blood pressure? A pilot study. Pharmacotherapy 1993;13(4):406–407.
177.
Anonymous. The effect of essential oil of garlic on hyperlipemia and platelet aggregation–an analysis of 308 cases. Cooperative Group for Essential Oil of Garlic. J Trad Chinese Med 
1986;6(2): 117–120.
178.
Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333(5): 276–282.
179.
Bakhit RM, Klein BP, Essex-Sorlie D, et al. Intake of 25 g of soybean protein with or without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. J Nutr 
1994;124(2): 213–222.
180.
Clarkson TB, Anthony MS, Williams JK, et al. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 1998;217(3):365–368.
181.
Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993;119(7 Pt 1):599–605.
182.
Silagy C, Neil A. Garlic as a lipid lowering agent–a meta-analysis. J Roy Coll Phys Lond 1994;28(1):39–45.
183.
Kendler BS. Garlic (Allium sativum) and onion (Allium cepa): a review of their relationship to cardiovascular disease. Prev Med 1987;16(5): 670–685.
184.
Rizzon P, Iliceto S, Marangelli V. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease. Cardiologia 1995;40(10):717–720.
185.
Greenberg SM, Frishman WH. Coenzyme Q10: a new drug for myocardial ischemia? Med Clin North Am 1988;72(1):243–258.
186.
Greenberg SM, Frishman WH. Coenzyme Q10: a new drug for myocardial ischemia? Med Clin North Am 1988;72(1):243–258.
187.
Roth A, Eshchar Y, Keren G, et al. Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient 
population. A pilot study. The Ichilov Magnesium Study Group. Eur Heart J 1994;15(9):1164–1173.
188.
Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–1449.
189.
Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–1456.
190.
Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 
1996;347:781–786.
191.
Tomoda H, Yoshitake M, Morimoto K, Aoki N. Possible prevention of postangioplasty restenosis by ascorbic acid. Am J Cardiol 1996;78(11): 1284–1286.
192.
Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93(6):1107–1113.
193.
Vita JA, Keaney JF Jr, Raby KE, et al. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol 1998;31(5):980–986.
194.
Connor WE. Do the n-3 fatty acids from fish prevent deaths from cardiovascular disease? Am J Clin Nutr 1997;66(1):188–189.
195.
Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res 1988;29(11):1451–1460.
196.
Connor WE. Effects of omega-3 fatty acids in hypertriglyceridemic states. Semin Thromb Hemost 1988;14(3):271–284.
197.
Braden GA, Knapp HR, FitzGerald GA. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 1991;84(2):679–685.
198.
Von Schacky C. Prophylaxis of atherosclerosis with marine omega-3 fatty acids: a comprehensive strategy. Ann Intern Med 1988;107:890–899.
199.
Ilsley CD, Nye ER, Sutherland W, et al. Randomized placebo-controlled trial of maxepa and aspirin/persantin after successful coronary angioplasty. Aust N Z J Med 1987;17(4):559. (Suppl 2).
200.
Milner MR, Gallino RA, Leffingwell A, et al. High-dose omega-3 fatty acid supplementation reduces clinical restenosis after angioplasty. Circulation 1988;78(Supp II):634.
201.
Slack JD, Pinkerton CA,Van Tassel J, et al. Can oral fish oil supplement minimize restenosis after percutaneous transluminal coronary angioplasty? J Am Coll Cardiol 1987;9(2):64A (Suppl A).
202.
Milner MR, Gallino RA, Leffingwell A, et al. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 
1989;64(5):294–299.
203.
Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 
1988;319(12):733–740.
204.
Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 1992;85(3):950–956.
205.
Nye ER, Ablett MB, Robertson MC, et al. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. 
Aust N Z J Med 1990;20(4):549–552.
206.
Mehta VY, Jorgensen MB, Raizner AE, et al. Spontaneous regression of restenosis: an angiographic study. J Am Coll Cardiol 1995;26(3): 696–702.
207.
O'Connor GT, Malenka DJ, Olmstead EM, et al. A meta-analysis of randomized trials of fish oil in prevention of restenosis following coronary angioplasty. Am J Prev Med 1992;8(3):186–192.
208.
Brensike JF, Kelsey SF, Passamani ER. National Heart, Lung, and Blood Institute Type II Coronary Intervention Study: design, methods, and baseline characteristics. Control Clin Trials 
1982;3:91–111.
209.
Brensike JF, Levy RI, Kelsey SF. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 
1984;69: 313–324.
210.
Blankenhorn DH, Nessim SA, Johnson RL. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.
211.
Blankenhorn DH, Johnson RL, Nessim SA. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987;8:354–387.
212.
Cashin-Hemphill L, Mack WJ, Pogoda JM. Beneficial effects of coletipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264: 3013–3017.
213.
Arntzenius AC, Kromhout D, Barth JD. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med 1985;312:805–811.
214.
Arntzenius AC. Diet, lipoproteins and the progression of coronary atherosclerosis. The Leiden Intervention Trial. Drugs 1986;31(Suppl 1):61–65.
215.
Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery 
disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89(3):975–990.
216.
Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 
1992;339(8793):563–569.
217.
Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids and progression of coronary artery disease in men. Am J Clin Nutr 1996;64(2): 202–209.
218.
Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264(23):3007–3012.
219.
Gould KL, Ornish D, Kirkeeide R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol 1992;69(9):845–853.
220.
Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 
1995;274(11):894–901.
221.
Flynn MK, Spann L, Sullivan MJ. Risk factor interventions and delayed progression of atherosclerosis. In: Rubin GS, Calff RM, O'Neill WW, et al, eds. Interventional cardiovascular medicine: 
principles and practice. New York: Churchill-Livingstone, 1994:108.
222.
Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86(1):1–11.
223.
Niebauer J, Hambrecht R, Velich T, et al. Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program. Am J Cardiol 
1996;78(2):163–167.
224.
Anonymous. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1994;17(5):519–530.
225.
Anderson JW, Geil PB. New perspectives in nutrition management of diabetes mellitus. Am J Med 1988;85(5A):159–165.
226.
Smith U. Carbohydrates, fat, and insulin action. Am J Clin Nutr 1994;59(Suppl 3):686S–689S.
227.
Anderson JW, Smith BM, Geil PB. High-fiber diet for diabetes. Safe and effective treatment. Postgrad Med 1990;88(2):157–161, 164, 167–168.
228.
Anderson JW. Recent advances in carbohydrate nutrition and metabolism in diabetes mellitus. J Am Coll Nutr 1989;8 (Suppl):61S–67S.
229.
Anderson JW, Gustafson NJ, Bryant CA, Tietyen-Clark J. Dietary fiber and diabetes: a comprehensive review and practical application. J Am Diet Assoc 1987;87(9):1189–1197.
230.
Uusitupa MI. Early lifestyle intervention in patients with non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Ann Med 1996;28(5):445–449.
231.
Berry EM. Dietary fatty acids in the management of diabetes mellitus. Am J Clin Nutr 1997;66(4 Suppl):991S–997S.
232.
Parillo M, Rivellese AA, Ciardullo AV, et al. A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in noninsulin-dependent diabetic patients. Metabolism 

1992;41(12):1373–1378.
233.
Berry EM. Dietary fatty acids in the management of diabetes mellitus. Am J Clin Nutr 1997;66(4 Suppl):991S–997S.
234.
Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 
1997;46(11):1786–1791.
235.
Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 1980;29(11):919–925.
236.
Wilson BE. Gondy A. Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. Diabetes Res Clin Pract 1995;28(3):179–184.
237.
Faure P, Roussel A, Coudray C, et al. Zinc and insulin sensitivity. Biol Trace Elem Res 1992;32:305–310.
238.
Sprietsma JE, Schuitemaker GE. Diabetes can be prevented by reducing insulin production. Med Hypotheses 1994;42(1):15–23.
239.
Engel ED, Erlick NE, Davis RH. Diabetes mellitus: impaired wound healing from zinc deficiency. J Am Podiatr Med Assoc 1981;71(10):536–544.
240.
Agren MS, Stromberg HE, Rindby A, Hallmans G. Selenium, zinc, iron and copper levels in serum of patients with arterial and venous leg ulcers. Acta Derm Venereol 1986;66(3):237–240.
241.
Paolisso G, Scheen A, D'Onofrio F, Lefebvre P. Magnesium and glucose homeostasis. Diabetologia 1990;33(9):511–514.
242.
Srivastava VK, Chauhan AK, Lahiri VL. The significance of serum magnesium in diabetes mellitus. Indian J Med Sci 1993;47(5):119–123.
243.
Grafton G, Baxter MA. The role of magnesium in diabetes mellitus. A possible mechanism for the development of diabetic complications. J Diabetes Complications 1992;6(2):143–149.
244.
Grafton G, Bunce CM, Sheppard MC, et al. Effect of Mg2+ on Na(+)-dependent inositol transport. Role for Mg2+ in etiology of diabetic complications. Diabetes 1992;41(1):35–39.
245.
White JR Jr, Campbell RK. Magnesium and diabetes: a review. Ann Pharmacother 1993;27(6): 775–780.
246.
Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 1996;156(11):1143–1148.
247.
Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 1992;19(2 Suppl):II26–II29.
248.
Thai AC, Husband DJ, Gill GV, Alberti KG. Management of diabetes during surgery. A retrospective study of 112 cases. Diabetes Metab 1984;10(2):65–70.
249.
Pezzarossa A, Taddei F, Cimicchi MC, et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. 
Diabetes Care 1988;11(1):52–58.
250.
Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab 1995;39(4):217–223.
251.
Rogers KS, Mohan C. Vitamin B6 metabolism and diabetes. Biochem Med Metab Biol 1994;52(1):10–17.
252.
Editorial. Vitamin B6 and diabetes. Lancet 1976;1(7963):788–789.
253.
Spellacy WN, Buhi WC, Birk SA. Vitamin B6 treatment of gestational diabetes mellitus: studies of blood glucose and plasma insulin. Am J Obstet Gynecol 1977;127(6):599–602.
254.
Rose DP, Leklem JE, Brown RR, Linkswiler HM. Effect of oral contraceptives and vitamin B6 deficiency on carbohydrate metabolism. Am J Clin Nutr 1975;28(8):872–878.
255.
Adams PW, Wynn V, Folkard J, Seed M. Influence of oral contraceptives, pyridoxine (vitamin B6), and tryptophan on carbohydrate metabolism. Lancet 1976;1(7963):759–764.
256.
Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol Med 1995;19(2):227–250.
257.
Roy S, Sen CK, Tritschler HJ, Packer L. Modulation of cellular reducing equivalent homeostasis by alpha-lipoic acid. Mechanisms and implications for diabetes and ischemic injury. Biochem 
Pharmacol 1997;53(3):393–399.
258.
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial 
(ALADIN Study). Diabetologia 1995;38(12): 1425–1433.
259.
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997;46(Suppl 2):S62–S66.
260.
Jacob S, Henriksen EJ, Tritschler HJ, et al. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol 
Diabetes 1996;104(3):284–288.
261.
Strodter D, Lehmann E, Lehmann U, et al. The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract 1995;29(1):19–26.
262.
Kilic F, Handelman GJ, Serbinova E, et al. Modelling cortical cataractogenesis 17: in vitro effect of a-lipoic acid on glucose-induced lens membrane damage, a model of diabetic 
cataractogenesis. Biochem Mol Biol Int 1995;37(2):361–370.
263.
Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann N Y Acad Sci 1994;738:257–264.
264.
McCarty MF. Maturity-onset diabetes mellitus–toward a physiological appropriate management. Med Hypotheses 1981;7(10):1265–1285.
265.
Barnard ND. Key nutrition issues for medical students. Washington, DC: Physicians Committee for Responsible Medicine 1997:3.
266.
Blackburn GL. Total parenteral nutrition. (Associate Professor of Surgery, Harvard Medical School.) Adjuvant Nutrition in Cancer Treatment Symposium. CTCA/American College of Nutrition. 
Tampa, Florida. September 19, 1995.
267.
Torosian MH, Daly JM. Nutritional support in the cancer-bearing host. Cancer 1986;58:1915–1929.
268.
Copeland EM, Daly JM, Dudrick SJ. Nutrition as an adjunct to cancer treatment in the adult. Cancer Res 1977;37:2451–2456.
269.
Mullen JL, Gertner MH, Buzby GP, et al. Implications of malnutrition in the surgical patient. Arch Surg 1979;114:121–125.
270.
Wyszynski DF, Crivelli A, Ezquerro S, Rodriguez A. Assessment of nutritional status in a population of recently hospitalized patients. Medicina 1998;58(1):51–57.
271.
MacBurney M, Young LS, Ziegler TR, Wilmore DW. A cost-evaluation of glutamine-supplemented parenteral nutrition in adult bone marrow transplant patients. J Am Diet Assoc 1994;94(11): 
1263–1266.
272.
Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled 
study. Ann Intern Med 1992;116(10):821–828.
273.
Young LS, Bye R, Scheltinga M, et al. Patients receiving glutamine-supplemented intravenous feedings report an improvement in mood. JPEN J Parenter Enteral Nutr 1993;17(5):422–427.
274.
Knutsen SF. Lifestyle and the use of health services. Am J Clin Nutr 1994;59(5 Suppl):1171S–1175S.
275.
Mills PK, Beeson WL, Phillips RL, Fraser GE. Cancer incidence among California Seventh-Day Adventists, 1976–1982. Am J Clin Nutr 1994;59(5 Suppl):1136S–1142S.
276.
Fraser GE, Beeson WL, Phillips RL. Diet and lung cancer in California Seventh-day Adventists. Am J Epidemiol 1991;133(7):683–693.
277.
Snowdon DA. Animal product consumption and mortality because of all causes combined, coronary heart disease, stroke, diabetes, and cancer in Seventh-day Adventists. Am J Clin Nutr 
1988;48(3 Suppl):739–748.
278.
Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984;120(2):244–250.
279.
Fonnebo V. Mortality in Norwegian Seventh-Day Adventists 1962–1986. J Clin Epidemiol 1992;45(2):157–167.
280.
Block KI. Adjuvant nutrition and nutritional pharmacology in cancer treatment: the emerging role of nutritional biotherapy in complementary oncology. Unpublished manuscript [under 
consideration for publication in the Archives of Internal Medicine for the spring of 1999].
281.
Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 1992;340(8828):1124–1127.
282.
Pike J, Chandra RK. Effect of vitamin and trace element supplementation on immune indices in healthy elderly. Int J Vitam Nutr Res 1995;65(2):117–121.
283.
Ascherio A, Rimm EB, Hernan MA, et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998;98:1198–1204.
284.
Bland JS. The use of complementary medicine for healthy aging. Altern Therap Health Med 1998;4(4):42–48.
285.
Bland JS. Psychoneuro-nutritional medicine: an advancing paradigm. Altern Therap Health Med 1995;1(2):22–27.
286.
Guthrie N, Gapor A, Chambers AF, et al. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and 
tamoxifen, alone and in combination. J Nutr 1997;127(3):544S–548S.
287.
Bollag W. The retinoid revolution. Overview. FASEB Journal 1996;10(9):938–939.

CHAPTER 30. M
EDITATION AND
 M
INDFULNESS
Essentials of Complementary and Alternative Medicine